New software aims to make liver cancer ablation more precise
NCT ID NCT04083378
First seen Nov 21, 2025 · Last updated Jun 20, 2026 · Updated 28 times
Summary
This phase 2 trial tests whether a software-aided imaging system (Morfeus) can help doctors confirm that liver tumors are fully covered during ablation. About 107 patients with up to 3 liver tumors will be treated with standard ablation, and the software will be used to assess the ablation margin. The goal is to see if this approach reduces the chance of tumor regrowth compared to the usual visual inspection of CT scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT LIVER NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Software-aided imaging (Morfeus)
What this could lead to
If successful, this could lead to more accurate liver tumor ablation, potentially reducing the chance of cancer returning after treatment.
What could go wrong
This is a phase 2 trial with only 107 participants, so results may not apply to everyone. The software may not improve outcomes significantly over standard methods.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.